Literature DB >> 27448405

Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.

Fabio Efficace1, Massimo Breccia2, Francesco Cottone3, Iris Okumura4, Maribel Doro4, Francesca Riccardi5, Gianantonio Rosti6, Michele Baccarani6.   

Abstract

PURPOSE: The main objective of this study was to investigate whether social support is independently associated with psychological well-being in chronic myeloid leukemia (CML) patients. Secondary objectives were to compare the psychological well-being profile of CML patients with that of their peers in general population and to examine possible age- and sex-related differences. PATIENTS AND METHODS: Analysis was performed on 417 patients in treatment with lifelong molecularly targeted therapies. Mean age of patients analyzed was 56 years (range 19-87 years) and 247 (59 %) were male and 170 (41 %) were female. Social support was assessed with the Multidimensional Scale of Perceived Social Support and psychological well-being was evaluated with the short version of the Psychological General Well-Being Index. Descriptive statistics and multivariate logistic regression analyses were used.
RESULTS: Multivariate logistic regression analysis revealed that a greater social support was independently associated with lower anxiety and depression, as well as with higher positive well-being, self-control, and vitality (p < 0.001). Female patients reported statistically significant worse outcomes in all dimensions of psychological well-being. Age- and sex-adjusted comparisons with population norms revealed that depression (ES = -0.42, p < 0.001) and self-control (ES = -0.48, p < 0.001) were the two main impaired psychological dimensions.
CONCLUSION: This study indicates that social support is a critical factor associated with psychological well-being of CML patients treated with modern lifelong targeted therapies.

Entities:  

Keywords:  Chronic myeloid leukemia; Leukemia; Psychological well-being; Social support; Target therapy; Tyrosine kinase inhibitors

Mesh:

Year:  2016        PMID: 27448405     DOI: 10.1007/s00520-016-3344-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  35 in total

1.  Social support and psychological distress in primary care attenders. Ferrara SIMG Group.

Authors:  L Grassi; G Rasconi; A Pedriali; A Corridoni; M Bevilacqua
Journal:  Psychother Psychosom       Date:  2000 Mar-Apr       Impact factor: 17.659

2.  Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.

Authors:  Carlo Gambacorti-Passerini; Laura Antolini; François-Xavier Mahon; Francois Guilhot; Michael Deininger; Carmen Fava; Arnon Nagler; Chiara Maria Della Casa; Enrica Morra; Elisabetta Abruzzese; Anna D'Emilio; Fabio Stagno; Philipp le Coutre; Rafael Hurtado-Monroy; Valeria Santini; Bruno Martino; Fabrizio Pane; Andrea Piccin; Pilar Giraldo; Sarit Assouline; Muheez A Durosinmi; Onno Leeksma; Enrico Maria Pogliani; Miriam Puttini; Eunjung Jang; Josy Reiffers; Maria Grazia Valsecchi; Dong-Wook Kim
Journal:  J Natl Cancer Inst       Date:  2011-03-21       Impact factor: 13.506

3.  The process of recovery from breast cancer for younger and older patients. Changes during the first year.

Authors:  A D Vinokur; B A Threatt; D Vinokur-Kaplan; W A Satariano
Journal:  Cancer       Date:  1990-03-01       Impact factor: 6.860

4.  Anxiety and depression in long-term testicular germ cell tumor survivors.

Authors:  S Vehling; A Mehnert; M Hartmann; C Oing; C Bokemeyer; K Oechsle
Journal:  Gen Hosp Psychiatry       Date:  2015-09-08       Impact factor: 3.238

Review 5.  Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.

Authors:  Jorge Cortes; Andreas Hochhaus; Timothy Hughes; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

6.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

Authors:  J E Sokal; E B Cox; M Baccarani; S Tura; G A Gomez; J E Robertson; C Y Tso; T J Braun; B D Clarkson; F Cervantes
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

7.  Social networks and quality of life among female long-term colorectal cancer survivors.

Authors:  Amy L Sapp; Amy Trentham-Dietz; Polly A Newcomb; John M Hampton; Carol M Moinpour; Patrick L Remington
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

8.  Association of social support, functional status, and psychological variables with changes in health-related quality of life outcomes in patients with colorectal cancer.

Authors:  M Gonzalez-Saenz de Tejada; A Bilbao; M Baré; E Briones; C Sarasqueta; J M Quintana; A Escobar
Journal:  Psychooncology       Date:  2015-11-18       Impact factor: 3.894

9.  The role of attachment dimensions and perceived social support in predicting adjustment to cancer.

Authors:  Viviana Cicero; Gianluca Lo Coco; Salvatore Gullo; Girolamo Lo Verso
Journal:  Psychooncology       Date:  2009-10       Impact factor: 3.894

10.  Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

Authors:  Annie Guérin; Lei Chen; Raluca Ionescu-Ittu; Maryna Marynchenko; Roy Nitulescu; Robert Hiscock; Christopher Keir; Eric Qiong Wu
Journal:  Curr Med Res Opin       Date:  2014-08-05       Impact factor: 2.580

View more
  7 in total

1.  Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.

Authors:  Qian Jiang; Hai-Bo Wang; Lu Yu; Robert Peter Gale
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-01       Impact factor: 4.553

2.  Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.

Authors:  Qian Jiang; Haibo Wang; Lu Yu; Robert Peter Gale
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-11       Impact factor: 4.553

3.  Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.

Authors:  Reinhard Stauder; Ge Yu; Karin A Koinig; Tim Bagguley; Pierre Fenaux; Argiris Symeonidis; Guillermo Sanz; Jaroslav Cermak; Moshe Mittelman; Eva Hellström-Lindberg; Saskia Langemeijer; Mette Skov Holm; Krzysztof Mądry; Luca Malcovati; Aurelia Tatic; Ulrich Germing; Aleksandar Savic; Corine van Marrewijk; Agnès Guerci-Bresler; Elisa Luño; Jackie Droste; Fabio Efficace; Alex Smith; David Bowen; Theo de Witte
Journal:  Leukemia       Date:  2018-03-06       Impact factor: 11.528

4.  Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees.

Authors:  Krish Patel; Vinjamuri S Sudhir; Shaum Kabadi; Joanna C Huang; Sanchita Porwal; Kushan Thakkar; John M Pagel
Journal:  J Oncol Pharm Pract       Date:  2019-02-05       Impact factor: 1.809

5.  Assessment of the health utility of patients with leukemia in China.

Authors:  Xueyun Zeng; Mingjie Sui; Rui Liu; Xinyu Qian; Wenfeng Li; Erwei Zheng; Jinjin Yang; Jinmei Li; Weidong Huang; Hongbin Yang; Hongjuan Yu; Nan Luo
Journal:  Health Qual Life Outcomes       Date:  2021-02-27       Impact factor: 3.186

6.  Psychological aspects in patients with advanced cancer receiving lifelong systemic treatment: protocol for a scoping review.

Authors:  Evie E M Kolsteren; Esther Deuning-Smit; Judith B Prins; Winette T A van der Graaf; Carla M L van Herpen; Sophie Lebel; Belinda Thewes; Linda Kwakkenbos; José A E Custers
Journal:  BMJ Open       Date:  2021-01-31       Impact factor: 2.692

7.  Relationship of Physicians' Rapport with Patients' Satisfaction and Psychological Well-being During Hospitalization.

Authors:  Muhammad Mubbashir Sheikh; Rehan Qayyum; Mukta Panda
Journal:  Cureus       Date:  2019-06-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.